



REMARKABLE SCIENCE. ENDURING PERFORMANCE.™

Revance Therapeutics
Investor Relations Department
7555 Gateway Boulevard
Newark, CA 94560
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RVNC


Last Trade:	35.95
Trade Time:	4:00 PM ET Dec 11, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	15.90 - 37.20
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comp... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 11, 2017 [Revance Announces Closing of Public Offering of Common Stock](#)
- Dec 7, 2017 [Revance Announces Pricing of Public Offering of Common Stock](#)
- Dec 5, 2017 [Revance Announces Proposed Public Offering of Common Stock](#)
- Dec 5, 2017 [Revance's RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines](#)
- Nov 29, 2017 [Revance Plans Phase 3 Program for RT002 Injectable to Treat Cervical Dystonia](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 28, 2017 [Annual Report \(10-K\)](#)
- Mar 24, 2017 [Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 4, 2017 [Quarterly Report \(10-Q\)](#)
- May 9, 2017 [Quarterly Report \(10-Q\)](#)